linjc16/ctgov huggingface dataset:
Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise

Study Overview
=================
Brief Summary
-----------------
The aim of the observational study is to ascertain the degree of blood pressure control in the early-morning hours after 8 weeks of treatment with Telmisartan/Telmisartan+Hydrochlorothiazide and during 44 weeks of follow-up, in patients with hypertension using home blood pressure measurements.

Official Title
-----------------
Study of Hypertensive Population Under Treatment With Micardis in Real Clinical Conditions With the Goal to Control the Early Morning BP Rise

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: telmisartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with mild to moderate essential hypertension and whose medical condition make them eligible for treatment with Telmisartan/Telmisartan+HCTZ Exclusion Criteria: Pre-menopausal women who had had no birth control, who are pregnant or nursing Patients with advanced hepatic impairment, advanced renal impairment or both Patients with functional class III or IV (NYHA) congestive heart failure (CHF), unstable angina, acute myocardial infarction, heart surgery or stroke within the previous six months Patients with any valvular disease with hemodynamic repercussion Patients receiving chronic administration of oral anticoagulants or digoxin Patients with known hypersensitivity to any component in the formulation of Micardis / MicardisPlus Patients with previous history of angioedema associated with ACE inhibitors Patients with severe, uncontrolled hypertension or any form of secondary hypertension Patients with any other clinical conditions which, in the opinion of the investigator, would not allow for the safe completion of the protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: telmisartan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in mean early morning systolic blood pressure, mean early morning diastolic blood pressure, and degree of control. (6:00 to 11:59), BP < 135/85 mmHg. (HBPM: mean of morning measurements). |  | 217 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical control (office BP), response rates, reduction in office cuff systolic and diastolic BP. Office BP control criteria: BP < 140/90 mmHg. Pulse rate, pulse pressure, discontinuations and tolerability. |  | 217 Weeks |
Different Treatment Options for Tubal Ectopic Pregnancy:- A Systmatic Review

Study Overview
=================
Brief Summary
-----------------
Ectopic pregnancy is an early pregnancy complication in which a fertilized ovum implant outside the uterine cavity. Implantation may occur anywhere along the reproductive tract with the most common implantation site being the fallopian tube. The incidence of ectopic pregnancy is 1% of pregnant women, and may seriously compromise women's health and future fertility. Currently, ectopic pregnancy can be often diagnosed before the woman's condition has deteriorated, which has altered the former clinical picture of a lifethreatening disease into a more benign condition in frequently asymptomatic women.

Official Title
-----------------
Different Treatment Options for Tubal Ectopic Pregnancy:- A Systmatic Review

Conditions
-----------------
Woman With Tubal Ectopic Pregnancy

Intervention / Treatment
-----------------
* Diagnostic Test: Serum beta HCG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: RCTs and observational studies All types of ectopic pregnancies. All types of treatments and medications for ectopic pregnancies. The long-term survival of patients with or without complications. Successful pregnancy and birth. Exclusion criteria: Articles of failed treatments of ectopic pregnancies. Articles with over all P value > 0.05. Articles for which the full text is not available in English.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Serum beta HCG|Raising numbers of S BHCG or decreasing with different management of tubal Ectopic Pregnancy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Abdominal and Transvaginal Ultrasound: | To detect the appearance of any mass at the adenexa,or intrauterine gestational sac in case of heterotopic pregnancy or misdiagnosis of ectopic pregnancy. To detect, if there's collection at the pelvis or freely at the abdomen in the case of disturbed ectopic pregnancy. | 6 Monthes | 
| S.bHCG: | in cases of expectant management,and medical treatment to detect level of S.bHCG after administration of methotrexate to decide to continue with medical treatment and give another doses or failure of this line and decide another line of management. Also,at the expectant management to close follow up the patient. | 6 Monthes | 
| Diagnostic laparoscopy | In cases of early,undisturbed ectopic pregnancy and may use also,for therapy Laparoscopic salpingostomy and/or salpingectomy | 6 Monthes |
Insulin Stimulated Vasodilation in Patients With Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
This study evaluates the role of endothelin in insulin stimulated vasodilation and glucose uptake. The subjects will complete an hyperinsulinemic euglycemic clamp with and without blockade of the endothelin receptors.

Official Title
-----------------
Insulin Stimulated Vasodilation in Patients With Type 2 Diabetes

Conditions
-----------------
Type2 Diabetes

Intervention / Treatment
-----------------
* Drug: Insulin clamp
* Drug: BQ123
* Drug: BQ123 + BQ788


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes OR healthy control (no type 2 diabetes) BMI<32 Exclusion Criteria: heart disease pregnancy or birth within 3 month smoking Kidney disease beta-blockers insulin treatment (for type 2 diabetics)

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Type 2 diabetics<br>BQ123 (25 nmol/min), BQ788 (25 nmol/min) | Drug: Insulin clamp<br>* Continous infusion insulin + glucose<br>Drug: BQ123<br>* Continuous infusion of Insulin + glucose + BQ123<br>Drug: BQ123 + BQ788<br>* Continous infusion of insulin + glucose + BQ123 + BQ788<br>|
| Experimental: Healthy controls<br>BQ123 (25 nmol/min), BQ788 (25 nmol/min) | Drug: Insulin clamp<br>* Continous infusion insulin + glucose<br>Drug: BQ123<br>* Continuous infusion of Insulin + glucose + BQ123<br>Drug: BQ123 + BQ788<br>* Continous infusion of insulin + glucose + BQ123 + BQ788<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose infusion rate | Glucose infusion rate required to maintain euglycemia during insulin clamp with and without endothelin blockade | 3.5 hours | 
| Leg blood flow | Effect of endothelin receptor blockade on leg blood flow (ultrasound Doppler) during insulin clamp with and without endothelin blockade | 3.5 hours |
The Prevalence of Metabolic Syndrome and Its Associated Factors in an Urban City

Study Overview
=================
Brief Summary
-----------------
The secondary objective is to evaluate the agreement between these criteria and the prevalence of concordant and discordant according to different criteria.

Detailed Description
-----------------
Up to now, there has been to uniform case definition for the metabolic syndrome. The World Health Organization and the Third Report of the National Cholesterol Education Program's Adult Treatment Panel (ATP III), and Bureau of Health Promotion, Taiwan proposed different criteria for the metabolic syndrome. Therefore, the secondary objective is to evaluate the agreement between these criteria and the prevalence of concordant and discordant according to different criteria. Three thousand persons will be randomly selected from resident of Taichung City. All the participants will fulfill a structured questionnaire. Blood pressure, anthropometric variables are measured. Biochemical markers are analyzed by a biochemical autoanalyzer. Kappa will be used to estimate the agreement between different criteria.

Official Title
-----------------
The Study for the Prevalence of Metabolic Syndrome and Its Associated Factors in an Urban City- Comparison of Agreement for Prevalence of Metabolic Syndrome Among the WHO, NCEP ATP III and Taiwan Definitions

Conditions
-----------------
Prediabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Residents aged 40 and over of Taichung City, Taiwan in October, 2004. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Intravascular Ultrasound Prediction of Myocardial Size and Coronary Computed Tomography-Derived Ischemic Burden for Coronary Lesion

Study Overview
=================
Brief Summary
-----------------
The aims of this study are 1) to identify IVUS determinants of the CAMS-derived myocardial territories subtended to the diseased vessels, 2) to find IVUS determinant for the extent of CAMS-derived myocardial size, and 3) to develop the mathematical model that integrates the IVUS information about myocardial territory and stenosis severity and predicts the extent of CAMS-derived myocardial size.

Official Title
-----------------
Intravascular Ultrasound Prediction of Myocardial Size and Coronary Computed Tomography-Derived Ischemic Burden for Coronary Lesion

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Other: Intravascular Ultrasound, coronary computed tomography angiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 20years or older Patients who have at least one epicardial coronary artery lesion (including isolated left main disease or side branch) with visually estimated diameter stenosis >50% and take coronary angiography, CT angiography and IVUS Willing and able to provide informed written consent Exclusion Criteria: In-stent restenosis Bypass graft Suspected coronary spasm even after sufficient nitrate injected Cases in which the IVUS imaging catheter failed to cross the lesion Poor quality IVUS or CT images Visible collateral flow on angiography

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| IVUS-CAMS<br>patients who undergo coronary computed tomography angiography, invasive coronary angiography and IVUS | Other: Intravascular Ultrasound, coronary computed tomography angiography<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mathematically-predicted ischemic size (by using IVUS parameters) vs. CAMS-derived myocardial size subtended to the stenotic segment |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of plaque characteristics (attenuated plaque, plaque rupture, calcification, thrombosis, etc.) assessed by IVUS on the ischemic burden assessed by CAMS |  | 1 year | 
| Incidence of MACE comprising death, nonfatal myocardial infarction or target vessel revascularization |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intravascular ultrasonography, Computed Tomography
Immediate Versus Later Insertion of IUD After Medical Termination of Pregnancy

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to compare, in a randomised, controlled and prospective fashion, initiation of intrauterine contraception (IUC) at about immediate (0 to 3 days) versus 2 to 4 weeks post medical abortion with regard to expulsions and use of contraception one year after abortion.

Official Title
-----------------
Immediate Versus Later Insertion of IUD After Medical Termination of Pregnancy

Conditions
-----------------
Contraception After Medical Abortion

Intervention / Treatment
-----------------
* Procedure: Immediate IUD insertion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years Planning medical abortion Planning LNG-IUD (Mirena) contraception Exclusion Criteria: Pathological pregnancies or abnormality of the uterus or cervix Acute endometritis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control group<br>Insertion of IUD at 2-4 weeks after abortion. | |
| Experimental: Immediate IUD insertion<br>Insertion of IUD immediately (at the same day to 3 days) after expulsion of placenta. | Procedure: Immediate IUD insertion<br>* Insertion of LNG-IUD (Mirena) (at the same day to 3 days) after expulsion of placenta.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of expulsions | Number of IUD expulsions | 1 year | 
| Use of IUD |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bleeding profile |  | 3 months | 
| Repeat abortions |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Abortion, Contraception, Intrauterine Devices, Intrauterine Device Expulsion
Personal Precise Treatment on Psoriasis and Psoriatic Arthritis

Study Overview
=================
Brief Summary
-----------------
Part of psoriasis and psoriatic arthritis patients treated with biologics and met primary failure. Therefore, we are going to create a cell based platform to evaluate the treatment effects of different biologics on psoriasis and psoriatic arthritis patients before prescribed by physicians

Detailed Description
-----------------
PBMCs isolated from psoriasis and psoriatic arthritis and incubated with Group A streptococcus and different biologics for 24 hours. Cytokines expression in the culture supernatants will be measured and the data can be reference for physician's prescription.

Official Title
-----------------
Personal Precise Treatment on Psoriasis and Psoriatic Arthritis and Investigate the Mechanisms of Biological Agents Induced Systemic Lupus Erythematosus

Conditions
-----------------
Dermatologic Disease

Intervention / Treatment
-----------------
* Diagnostic Test: Markers data from PBMCs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Healthy control without underline disease such as psoriasis and psoriatic arthritis. 2. Psoriasis been diagnosed for over six months and PASI >10. 3.Psoriatic arthritis been diagnosed for over six months and >1 swallow and tender joints Exclusion Criteria: nil

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Prescreen on psoriasis and psoriatic arthritis treatment<br>Prescreen markers from individual PBMCs and choose proper biologics before starting treatment on psoriasis and psoriatic arthritis patients. | Diagnostic Test: Markers data from PBMCs<br>* Prescreen markers from patient individual PBMCs treating with streptococcus and different biologics.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PASI score | Psoriasis skin condition and severity | 2 weeks to 3 months | 
| swelling joint count and tenderness joint count | PSA severity | 2 weeks to 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CRP | blood test | 3-6 months | 
| DLQI | paper to investigate patient life quality | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PSO, PSA, SLE, PBMC
Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.

Detailed Description
-----------------
PROTOCOL OUTLINE: This protocol describes several clinical studies of pharmacologic and dietary management in patients with urea cycle disorders. Patients with carbamyl phosphate synthetase and ornithine transcarbamylase deficiency are treated with a low-protein diet, essential amino acids (for neonatal onset disease), caloric supplementation, oral sodium phenylbutyrate (now approved as a prescription drug 11/97), and citrulline or arginine free base. Patients with argininosuccinic acid synthetase deficiency are treated with a low-protein diet, caloric supplementation, oral sodium phenylbutyrate (now approved as a prescription drug 11/97), and arginine free base. Patients with argininosuccinic aciduria (AA) are treated with a low-protein diet, caloric supplementation, and arginine free base. (Discontinued 11/97) Any patient who develops hyperammonemia is treated with intravenous sodium benzoate, sodium phenylbutyrate, and arginine hydrochloride; benzoate and phenylbutyrate are not given to patients with AA. If ammonium stabilizes at normal or near normal levels, intravenous medications are gradually replaced by oral medications. If there is no significant decrease in ammonium within 8 hours, patients begin hemodialysis. Concurrent therapy with ondansetron, high caloric intake, and mannitol for elevated intracranial pressure is allowed. Dietary and intravenous nitrogen is prohibited. (Discontinued 11/97)

Conditions
-----------------
Amino Acid Metabolism, Inborn Errors

Intervention / Treatment
-----------------
* Drug: Sodium Benzoate
* Drug: Sodium Phenylacetate
* Drug: Sodium Phenylbutyrate
* Behavioral: Dietary Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: Urea cycle deficiency, i.e.: Carbamyl phosphate synthetase deficiency (CPSD) Ornithine transcarbamylase deficiency (OTCD) Argininosuccinic acid synthetase deficiency (ASD) Argininosuccinic aciduria (AA)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Sodium Benzoate|nan|
|Drug: Sodium Phenylacetate|nan|
|Drug: Sodium Phenylbutyrate|nan|
|Behavioral: Dietary Intervention|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
inborn errors of metabolism, rare disease, urea cycle disorder